Cerda Ivo H, Jung Helen, Guerrero Maria C, Diez Tafur Rodrigo, Yong Robert Jason, Robinson Christopher L, Hasoon Jamal J
Harvard Medical School, Boston, MA 02115, USA.
Albert Einstein College of Medicine, Bronx, NY 10461, USA.
J Clin Med. 2025 Apr 19;14(8):2823. doi: 10.3390/jcm14082823.
Celecoxib, a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID), is widely prescribed for pain management due to its efficacy and improved gastrointestinal safety profile compared to traditional NSAIDs. Understanding prescription trends and their comparison to other NSAIDs provides valuable insight into prescribing behaviors in clinical settings. This retrospective study analyzed celecoxib prescriptions written by three pain management physicians in a single institution over a 16-month period from 1 January 2023 to 30 April 2024. Prescription data were collected and grouped into four 4-month intervals to assess temporal trends. Additionally, we compared celecoxib prescriptions to other commonly prescribed NSAIDs, including ibuprofen, meloxicam, naproxen, and diclofenac. A total of 143 celecoxib prescriptions were identified during the study period, with a steady increase observed across consecutive intervals: 8 prescriptions from January-April 2023, 22 from May-August 2023, 46 from September-December 2023, and 67 from January-April 2024. In comparison, a total of 165 prescriptions were written for other NSAIDs over the same period, with 26 prescriptions from January-April 2023, 41 from May-August 2023, 45 from September-December 2023, and 53 from January-April 2024. While prescriptions for both celecoxib and other NSAIDs increased over time, the rate of celecoxib prescriptions showed a steeper rise. The findings demonstrate a notable increase in celecoxib prescriptions in this pain management clinic, outpacing the growth of other NSAIDs. This trend may reflect increasing provider preference for COX-2 selective inhibitors due to their favorable safety profile and efficacy. Further research is warranted to explore the underlying factors driving these prescribing patterns.
塞来昔布是一种COX-2选择性非甾体抗炎药（NSAID），因其疗效以及与传统NSAIDs相比改善的胃肠道安全性，被广泛用于疼痛管理。了解其处方趋势以及与其他NSAIDs的比较，可为临床环境中的处方行为提供有价值的见解。这项回顾性研究分析了2023年1月1日至2024年4月30日这16个月期间，一家机构的三名疼痛管理医生开具的塞来昔布处方。收集处方数据并将其分为四个4个月的时间段，以评估时间趋势。此外，我们将塞来昔布处方与其他常用的NSAIDs进行了比较，包括布洛芬、美洛昔康、萘普生和双氯芬酸。在研究期间共确定了143份塞来昔布处方，在连续的时间段中观察到稳步增加：2023年1月至4月有8份处方，2023年5月至8月有22份，2023年9月至12月有46份，2024年1月至4月有67份。相比之下，同期其他NSAIDs共开具了165份处方，2023年1月至4月有26份，2023年5月至8月有41份，2023年9月至12月有45份，2024年1月至4月有53份。虽然塞来昔布和其他NSAIDs的处方量都随时间增加，但塞来昔布处方的增长率上升得更快。研究结果表明，在这个疼痛管理诊所中，塞来昔布处方量显著增加，超过了其他NSAIDs的增长。这种趋势可能反映出由于其良好的安全性和疗效，医疗服务提供者对COX-2选择性抑制剂的偏好增加。有必要进行进一步研究，以探索驱动这些处方模式的潜在因素。
